Table 1.
Demographic and risk factors of included PAD patients
| Characteristics | Indigenous (n = 16) | Non-Indigenous (n = 385) | p-value |
|---|---|---|---|
| Age (y) | 63.3 (54.7–67.8) | 69.6 (63.3–75.4) | 0.005 |
| Sex (% Males) | 10 (62.5%) | 293 (76.1%) | 0.215 |
| Diabetes mellitus | 7 (43.8%) | 103 (26.8%) | 0.135 |
| Smoker | 0.041 | ||
| Never | 0 (0%) | 82 (21.3%) | |
| Current | 9 (56.3%) | 121 (31.4%) | |
| Previous | 7 (43.8%) | 182 (47.3%) | |
| Hypertension | 15 (93.8%) | 290 (75.3%) | 0.091 |
| IHD | 10 (62.5%) | 164 (42.6%) | 0.116 |
| Stroke | 1 (6.3%) | 38 (9.9%) | 0.632 |
| eGFR (mL/min/1.73m2) | 79.0 (46.5–85.8) [2]a | 78 (60.0–91.0) [93]a | 0.416 |
| Medications | |||
| Aspirin | 11 (68.88%) | 252 (65.5%) | 0.786 |
| Other antiplatelet | 3 (18.8%) | 66 (17.1%) | 0.867 |
| Frusemide | 4 (25.0%) | 28 (7.3%) | 0.010 |
| ACEI | 10 (62.5%) | 152 (39.5%) | 0.066 |
| Beta-Blocker | 6 (37.5%) | 115 (29.9%) | 0.515 |
| Calcium channel blocker | 3 (18.8%) | 115 (29.9%) | 0.339 |
| Metformin | 4 (25.0%) | 69 (17.9%) | 0.472 |
| Insulin | 3 (18.8%) | 20 (5.2%) | 0.022 |
| Statin | 13 (81.3%) | 273 (70.9%) | 0.370 |
IHD ischaemic heart disease, eGFR estimated glomerular filtration rate, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
aRepresents the number of missing data-points. Continuous data are presented as median [interquartile range] and were compared using Mann-Whitney U test. Nominal data are presented as number (%) and were compared using Pearson’s χ2 test. P-values highlighted in bold indicate significant differences